GSK plc
GSK
$52.96
$0.791.51%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.35% | -11.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.35% | -11.99% | |||
| Cost of Revenue | 10.75% | -28.85% | |||
| Gross Profit | 10.22% | -4.64% | |||
| SG&A Expenses | 5.25% | -22.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 66.79% | -40.88% | |||
| Total Operating Expenses | 19.60% | -30.83% | |||
| Operating Income | -5.89% | 68.73% | |||
| Income Before Tax | -83.47% | 124.37% | |||
| Income Tax Expenses | -165.32% | 35.98% | |||
| Earnings from Continuing Operations | -69.90% | 151.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -15.82% | -11.44% | |||
| Net Income | -74.93% | 171.53% | |||
| EBIT | -5.89% | 68.73% | |||
| EBITDA | -12.47% | 19.46% | |||
| EPS Basic | -74.86% | 171.21% | |||
| Normalized Basic EPS | -6.60% | 82.66% | |||
| EPS Diluted | -74.86% | 172.26% | |||
| Normalized Diluted EPS | -6.54% | 83.36% | |||
| Average Basic Shares Outstanding | -0.22% | 0.10% | |||
| Average Diluted Shares Outstanding | -0.29% | -0.29% | |||
| Dividend Per Share | 0.09% | -6.10% | |||
| Payout Ratio | 3.51% | -0.64% | |||